Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $108,000.

  • 4D Molecular Therapeutics' Other Accumulated Expenses fell 13.60% to $108,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $108,000, marking a year-over-year decrease of 13.60%. This contributed to the annual value of $114,000 for FY2024, which is 9.62% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Other Accumulated Expenses is $108,000, which was up 5.88% from $102,000 recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Other Accumulated Expenses high stood at $1.8 million for Q4 2021, and its period low was $45,000 during Q1 2023.
  • In the last 3 years, 4D Molecular Therapeutics' Other Accumulated Expenses had a median value of $108,000 in 2025 and averaged $110,091.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Other Accumulated Expenses soared by 260.49% in 2021, and later plummeted by 93.18% in 2023.
  • 4D Molecular Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.8 million in 2021, then slumped by 78.42% to $382,000 in 2022, then plummeted by 72.77% to $104,000 in 2023, then increased by 9.62% to $114,000 in 2024, then decreased by 13.60% to $108,000 in 2025.
  • Its last three reported values are $108,000 in Q3 2025, $102,000 for Q2 2025, and $161,000 during Q1 2025.